Радиочастотная (микроволновая) абляция злокачественных и доброкачественных новообразований щитовидной железы

1. Протоколы заседаний Объединенной комиссии по качеству медицинских услуг МЗ РК, 2020
   1. 1) 2017 Thyroid Radiofrequency Ablation Guideline: Korean Society of Thyroid RadiologyJi-hoon Kim, MD, PhD, Jung Hwan Baek, MD, PhD, Hyun Kyung Lim, MDKorean J Radiol 2018;19(4):632-655 2) Радиочастотная термоаблация опухолей: Долгушин Б.И., Косырев В. Ю. Практическая медицина 2015.:192стр 3) Na DG, Lee JH, Jung SL, Kim JH, Sung JY, Shin JH, et al.; Korean Society of Thyroid Radiology (KSThR); Korean Society of Radiology. Radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: consensus statement and recommendations. Korean J Radiol 2012;13:117-125 4) Bandeira-Echtler E, Bergerhoff K, Richter B. Levothyroxine or minimally invasive therapies for benign thyroid nodules. Cochrane Database Syst Rev 2014: 5) Mauri G, Cova L, Monaco CG, Sconfienza LM, Corbetta S, Benedini S, et al. Benign thyroid nodules treatment using percutaneous laser ablation (PLA) and radiofrequency ablation (RFA). Int J Hyperthermia 2016 Nov 15 [Epub ahead of print]. 6) Deandrea M, Limone P, Basso E, Mormile A, Ragazzoni F, Gamarra E, et al. US-guided percutaneous radiofrequency thermal ablation for the treatment of solid benign hyperfunctioning or compressive thyroid nodules. Ultrasound Med Biol 2008;34:784-791 7) Jeong WK, Baek JH, Rhim H, Kim YS, Kwak MS, Jeong HJ, et al. Radiofrequency ablation of benign thyroid nodules: safety and imaging follow-up in 236 patients. EurRadiol 2008;18:1244-1250 8) Kim YS, Rhim H, Tae K, Park DW, Kim ST. Radiofrequencyablation of benign cold thyroid nodules: initial clinicalexperience. Thyroid 2006;16:361-367 9) Spiezia S, Garberoglio R, Milone F, Ramundo V, Caiazzo C,Assanti AP, et al. Thyroid nodules and related symptomsare stably controlled two years after radiofrequency thermalablation. Thyroid 2009;19:219-225 10) Baek JH, Jeong HJ, Kim YS, Kwak MS, Lee D. Radiofrequencyablation for an autonomously functioning thyroid nodule.Thyroid 2008;18:675-676 11) Baek JH, Kim YS, Lee D, Huh JY, Lee JH. Benignpredominantly solid thyroid nodules: prospective studyof efficacy of sonographically guided radiofrequencyablation versus control condition. AJR Am J Roentgenol2010;194:1137-1142 12) Lee JH, Kim YS, Lee D, Choi H, Yoo H, Baek JH.Radiofrequency ablation (RFA) of benign thyroid nodules inpatients with incompletely resolved clinical problems afterethanol ablation (EA). World J Surg 2010;34:1488-1493 13) Sung JY, Kim YS, Choi H, Lee JH, Baek JH. Optimum firstline treatment technique for benign cystic thyroid nodules:ethanol ablation or radiofrequency ablation? AJR Am JRoentgenol 2011;196:W210-W214 14) Jung SL, Baek JH, Lee JH, Shong YK, Sung JY, Kim KS, etal. Efficacy and safety of radiofrequency ablation for benignthyroid nodules: a prospective multicenter study. Korean JRadiol 2018;19:167-174 15) Baek JH, Na DG, Lee JH, Jung SL, Sung JY, Sim JS. Korean society of thyroid radiology recommendations for radiofrequency ablation of thyroid nodules. Korean Society of Thyroid Radiology, 2009. Available at: http://thyroidimaging.kr/. Accessed June 1, 2016 16) Choi SJ, Jeong WK, Jo AJ, Choi JA, Kim MJ, Lee M, et al. Methodology for developing evidence-based clinical imaging guidelines: joint recommendations by Korean Society of Radiology and National Evidence-based Healthcare Collaborating Agency. Korean J Radiol 2017;18:208-216 17) Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al.; QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529-536 18) Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1-133 19) Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, FalckYtter Y, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J ClinEpidemiol 2013;66:719-725 20) Jang SW, Baek JH, Kim JK, Sung JY, Choi H, Lim HK, et al. How to manage the patients with unsatisfactory results after ethanol ablation for thyroid nodules: role of radiofrequency ablation. Eur J Radiol 2012;81:905-910 21) Park HS, Baek JH, Na DG. Benign thyroid nodules treatment using percutaneous laser ablation (PLA) and radiofrequency ablation (RFA). Int J Hyperthermia 2017;33:953-954 22) Eng OS, Potdevin L, Davidov T, Lu SE, Chen C, Trooskin SZ. Does nodule size predict compressive symptoms in patients with thyroid nodules? Gland Surg 2014;3:232-236 23) Banks CA, Ayers CM, Hornig JD, Lentsch EJ, Day TA, Nguyen SA, et al. Thyroid disease and compressive symptoms. Laryngoscope 2012;122:13-16 24) Committee. IPA. Ultrasound-guided percutaneous radiofrequency ablation for benign thyroid nodules. Interventional procedures guidance https://www.nice.org.uk/Guidance/IPG562. Published June, 2016. Accessed Dec 1, 2016 25) Shin JH, Baek JH, Chung J, Ha EJ, Kim JH, Lee YH, et al. Ultrasonography diagnosis and imaging-based management of thyroid nodules: revised Korean Society of Thyroid Radiology consensus statement and recommendations. Korean J Radiol 2016;17:370-395 26) Gharib H, Papini E, Garber JR, Duick DS, Harrell RM, Hegedüs L, et al.; AACE/ACE/AME Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules - 2016 update. EndocrPract 2016;22:622-639. 27) Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Thyroid 2009;19:1159-1165 28) Na DG, Baek JH, Jung SL, Kim JH, Sung JY, Kim KS, et al. Core needle biopsy of the thyroid: 2016 consensus statement and recommendations from Korean Society of Thyroid Radiology. Korean J Radiol 2017;18:217-237 29) Hong MJ, Na DG, Baek JH, Sung JY, Kim JH. Cytologyultrasonography risk-stratification scoring system based on fine-needle aspiration cytology and the Korean-thyroid imaging reporting and data system. Thyroid 2017;27:953-959 30) McCoy KL, Jabbour N, Ogilvie JB, Ohori NP, Carty SE, Yim JH. The incidence of cancer and rate of false-negative cytology in thyroid nodules greater than or equal to 4 cm in size. Surgery 2007;142:837-844; discussion 844.e1-3 31) Mehanna R, Murphy M, McCarthy J, O’Leary G, Tuthill A, Murphy MS, et al. False negatives in thyroid cytology: impact of large nodule size and follicular variant of papillary carcinoma. Laryngoscope 2013;123:1305-1309 32) Agcaoglu O, Aksakal N, Ozcinar B, Sarici IS, Ercan G, Kucukyilmaz M, et al. Factors that affect the false-negative outcomes of fine-needle aspiration biopsy in thyroid nodules. Int J Endocrinol 2013;2013:126084 33) Giles WH, Maclellan RA, Gawande AA, Ruan DT, Alexander EK, Moore FD Jr, et al. False negative cytology in large thyroid nodules. Ann SurgOncol 2015;22:152-157 34) Shin JJ, Caragacianu D, Randolph GW. Impact of thyroid nodule size on prevalence and post-test probability of malignancy: a systematic review. Laryngoscope 2015;125:263-272 35) Koo DH, Song K, Kwon H, Bae DS, Kim JH, Min HS, et al. Does tumor size influence the diagnostic accuracy of ultrasound-guided fine-needle aspiration cytology for thyroid nodules? Int J Endocrinol 2016; 36) Cavallo A, Johnson DN, White MG, Siddiqui S, Antic T, Mathew M, et al. Thyroid nodule size at ultrasound as a predictor of malignancy and final pathologic size. Thyroid 2017;27:641-650 37) Magister MJ, Chaikhoutdinov I, Schaefer E, Williams N, Saunders B, Goldenberg D. Association of thyroid nodule size and bethesda class with rate of malignant disease. JAMA Otolaryngol Head Neck Surg 2015;141:1089-1095 38) Kamran SC, Marqusee E, Kim MI, Frates MC, Ritner J, Peters H, et al. Thyroid nodule size and prediction of cancer. J ClinEndocrinolMetab 2013;98:564-570 39) Rossi ED, Bizzarro T, Fadda G, Pontecorvi A, Bernet V, Nassar A. The cytological diagnosis of a ‘benign thyroid lesion’: is it a real safe diagnosis for the patient? Cytopathology 2016;27:168-175 40) Kulstad R. Do all thyroid nodules> 4 cm need to be removed? An evaluation of thyroid fine-needle aspiration biopsy in large thyroid nodules. EndocrPract 2016;22:791-798 41) Shi H, Bobanga I, McHenry CR. Are large thyroid nodules classified as benign on fine needle aspiration more likely to harbor cancer? Am J Surg 2017;213:464-466 42) Orlandi A, Puscar A, Capriata E, Fideleff H. Repeated fineneedle aspiration of the thyroid in benign nodular thyroid disease: critical evaluation of long-term follow-up. Thyroid 2005;15:274-278 43) Moon WJ, Jung SL, Lee JH, Na DG, Baek JH, Lee YH, et al.; Thyroid Study Group, Korean Society of Neuro- and Head and Neck Radiology. Benign and malignant thyroid nodules: US differentiation--multicenter retrospective study. Radiology 2008;247:762-770 44) Bonavita JA, Mayo J, Babb J, Bennett G, Oweity T, Macari M, et al. Pattern recognition of benign nodules at ultrasound of the thyroid: which nodules can be left alone? AJR Am J Roentgenol 2009;193:207-213 45) Kim JY, Jung SL, Kim MK, Kim TJ, Byun JY. Differentiation of benign and malignant thyroid nodules based on the proportion of sponge-like areas on ultrasonography: imagingpathologic correlation. Ultrasonography 2015;34:304-311

ОРГАНИЗАЦИОННЫЕ АСПЕКТЫ ПРОТОКОЛА

Список разработчиков протокола с указанием квалификационных данных:
 1) Малаев Нияз Бейсенович – MD, MMSc, MBA, интервенционный радиолог,  онколог АО «Национальный научный  медицинский центр».
2) Иманкулов Суюндук Бопежанович – доктор медицинских наук, руководитель отдела ультразвуковой диагностики и HIFU терапии, врач высшей квалификационной категории  АО «Национальный научный  медицинский центр».
 3) Косырев Владислав Юрьевич – доктор медицинских наук, ведущий научный сотрудник НМИЦ онкологии им. Н.Н. Блохина    Минздрава России. Доцент кафедры онкологии ПММУ им. И.М. Сеченова. Исполнительный директор  Российского общества интервенционных онкорадиологов.
 4) Жанпеисов Нурлан Каиржанович – магистр медицины, врач высшей квалификационной категории отдела ультразвуковой диагностики и HIFU терапии,  врач высшей квалификационной категории    АО «Национальный научный  медицинский центр».
5) Кубекова Сауле Жадраевна – MD, PhD ассистент кафедры Внутренних болезней №3 НАО «Медицинский университет Астана».
 
Указание на отсутствие конфликта интересов: нет.  
 
Рецензент:
1) Ижанов Е.Б. – доктор медицинских наук, Руководитель центра абдоминальной онкологии. Председатель хирургического совета АО «Казахский научно-исследовательский институт онкологии и радиологии». 
 
Указание условий пересмотра протокола: пересмотр протокола через 5лет после его опубликования и с даты его вступления в действие или при наличии новых методов с уровнем доказательности.